SURVIVAL OUTCOMES AND SOME RELATED FACTORS IN THE TREATMENT OF RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA WITH R-GEMOX REGIMEN AT K HOSPITAL
.
Abstract
Objective: To evaluate the survival outcomes and some related factors of R-GEMOX chemotherapy regimen in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma at K Hospital from 2019 to 2024.
Subjects and methods: A cross-sectional descriptive study was conducted on 83 patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with RGEMOX regimen at the Hematologic oncology department, K Hospital from May 2019 to June 2024. Results: The average age was 59.9; the male/female ratio was 1; The overall response rate was 51.8%, of which the complete response rate was 20.5%; partial response was 31.3%; The rate of stable disease was 4.8%; the rate of progression disease was 43.4%; The median progression-free survival of the study was 13 months. The median overall survival of the study was 21 months. Refractory was an independent prognostic factor for PFS (p<0.05) and response after treatment was an independent prognostic factor for progression-free survival and overall survival with p<0.001.
Conclusion: R-GEMOX regimen prolongs progression-free survival as well as overall survival and is safe for patients with relapsed/refractory B-cell non-Hodgkin lymphoma without high-dose chemotherapy indications.
.
Keywords
R/R NHL (Relapsed/Refractory B-cell non-Hodgkin lymphoma)
- Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. . N Engl J Med. 1995;333:1540–1545.
- Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progressionfree survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918–3927.
- T. El Gnaoui, J. Dupuis, K. Belhadj et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Annals of Oncology. 2007:1363–1368.
- Fossa A, Santoro A, Hiddemann W et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3786–3792.
- Andrew D.Z. et al. NCCN Clinical practice guidelines in Oncology - B-Cell lymphomas. NCCN. 2020:12-65.
- Clarisse Cazelles, Karim Belhadj, Hélène Vellemans et al. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leuk Lymphoma. 2021;62(9):2161-2168.
